TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9581739

Group type: COMPARATOR
Intervention: Single-coil configuration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dual-coil configuration
Number of subjects: 50
Study: 9419761

Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (venipuncture)
Number of subjects: 42
Study: 2927460

Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms per kilogram of body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison group of 10 non-smokers
Number of subjects: 10
Study: 14673617

Group type: EXPERIMENTAL
Intervention: GaAs laser treatment applied over three trigger points bilaterally and one point in the taut bands in trapezius muscle bilaterally with a frequency of 1000 Hz for 2 min over each point once a day for 10 days during a period of 2 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo treatment (laser instrument switched off) with the same treatment protocol
Number of subjects: 53
Study: 31048013

Group type: EXPERIMENTAL
Intervention: Cyclosporine (4 mg/kg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28507108

Group type: EXPERIMENTAL
Intervention: ABX464 (up to 150 mg once a day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 26644127

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT) combined with motor and sensory‐motor interventions
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard of care occupational and physical therapy
Number of subjects: 216
Study: 23547654

Group type: EXPERIMENTAL
Intervention: Patient-centred care pathway developed for transition from hospital to follow-up in primary care.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Disease-based care pathways used within hospitals.
Number of subjects: 3
Study: 21748303

Group type: EXPERIMENTAL
Intervention: Bread fortified with ferrous sulfate (labeled with (59)Fe as sulfate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bread fortified with ferrous fumarate (labeled with (55)Fe as fumarate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects consuming bread fortified with ferrous sulfate
Number of subjects: 50

Group type: COMPARATOR
Intervention: H. pylori-positive subjects consuming bread fortified with ferrous sulfate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects consuming bread fortified with ferrous fumarate
Number of subjects: 50

Group type: COMPARATOR
Intervention: H. pylori-positive subjects consuming bread fortified with ferrous fumarate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: After administration of a proton pump inhibitor
Number of subjects: 50
Study: 19922603

Group type: EXPERIMENTAL
Intervention: Postural exercise therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 88
Study: 16508401

Group type: EXPERIMENTAL
Intervention: Ketamine (0.24 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study: 14720267

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray 220 microg once daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray
Number of subjects: 23
Study: 10675426

Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Thalamotomy
Number of subjects: 68
Study: 9313671

Group type: EXPERIMENTAL
Intervention: Spermatic-cord block (10 mL of 0.5% plain bupivacaine)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional analgesic regimen (general anaesthesia, fentanyl, and diclofenac)
Number of subjects: 48
Study: 8370132

Group type: EXPERIMENTAL
Intervention: Oral melatonin (10 mg) administered 60 minutes prior to GHRH (100 micrograms i.v. bolus)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral melatonin (10 mg) administered 60 minutes prior to a submaximal dose (3 micrograms i.v. bolus) of GHRH
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral pyridostigmine (120 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of melatonin (10 mg) and pyridostigmine (120 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3011310

Group type: EXPERIMENTAL
Intervention: 0.5 mg nedocromil sodium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.0 mg nedocromil sodium
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2.0 mg nedocromil sodium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31951148

Group type: EXPERIMENTAL
Intervention: Standardized controlling method (S-K)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Limited controlling method (L-K)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tell-Show-Do Method (TSDM)
Number of subjects: 60
Study: 29722640

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 26821260

Group type: EXPERIMENTAL
Intervention: Group physiotherapy
Number of subjects: 12
Study: 23942245

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 459

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study: 21948807

Group type: EXPERIMENTAL
Intervention: Plain packaging
Number of subjects: 52

Group type: COMPARATOR
Intervention: Coloured packaging
Number of subjects: 52
Study: 20304566

Group type: EXPERIMENTAL
Intervention: 15 Gy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 20 Gy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 25 Gy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Overall (all doses)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison between 25 Gy and lower doses (20 Gy and 15 Gy)
Number of subjects: 73
Study: 19102184

Group type: EXPERIMENTAL
Intervention: T shape approach (Group B)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Traditional exposure approach (Group A)
Number of subjects: 113
Study: 15647648

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (n=28)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Dual therapy (n=30)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Triple therapy (n=27)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Lansoprazole and placebo (n=30)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients using NSAIDs or ASA
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients using NSAIDs or ASA
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients not using NSAIDs or ASA
Number of subjects: 115
Study: 12038875

Group type: EXPERIMENTAL
Intervention: Directive parent education and behavior modification techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delorazepam (chlordesmethyldiazepam)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niaprazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alimemazine (trimeprazine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer hypnotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotherapy or medical management
Number of subjects: 0
Study: 9485131

Group type: EXPERIMENTAL
Intervention: Controlled‐onset extended release (COER) verapamil
Number of subjects: 557

Group type: COMPARATOR
Intervention: Nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 557
Study: 7666101

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily on days 2 and 3 and placebo on days 4 to 6
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily on days 2 to 6
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo on days 2 to 6
Number of subjects: 538
Study: 2787477

Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy for ALL
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: T-cell immunophenotype
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Cytogenetic studies
Number of subjects: 733
Study: 1131555

Group type: EXPERIMENTAL
Intervention: Behaviour therapy conducted by medical students
Number of subjects: 12
Study: 31846980

Group type: EXPERIMENTAL
Intervention: Active tACS (20 daily 40-min sessions, 77.5-Hz, 15-mA)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Active tACS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 62
Study: 30095983

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision-support systems (CCDSS) after computer-based simulation (CBS) training
Number of subjects: 1051

Group type: COMPARATOR
Intervention: No further intervention (comparison arm)
Number of subjects: 1051
Study: 28587498

Group type: EXPERIMENTAL
Intervention: 2mA cathodal tDCS for 10 minutes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham tDCS for 10 minutes
Number of subjects: 6
Study: 25280931

Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (MAN)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Stretching of the Lumbar spine (STR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham manipulation (SHA)
Number of subjects: 27
Study: 23743976

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID (DE 110)
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID (DE 150)
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study: 21393113

Group type: EXPERIMENTAL
Intervention: Milk containing synbiotics (Bifidobacterium longum, Lactobacillus rhamonosus, prebiotics) and LCPUFA
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Milk containing synbiotics
Number of subjects: 393
Study: 19057983

Group type: EXPERIMENTAL
Intervention: ALA-PDT with 60 mg/kg and red laser light (1,000 J/cm)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ALA-PDT with 30 mg/kg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: ALA-PDT with 60 mg/kg and red laser light
Number of subjects: 48
Study: 16541846

Group type: EXPERIMENTAL
Intervention: Test group (14 subjects) wearing test shoes with insoles that stimulated the plantar surfaces
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (10 subjects) wearing placebo shoes
Number of subjects: 24
Study: 14681639

Group type: EXPERIMENTAL
Intervention: Topically applied frozen autologous platelets (FAP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 15
Study: 16634116

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg b.i.d.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg b.i.d.
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Exenatide (both dosages)
Number of subjects: 222
Study: 10504642

Group type: EXPERIMENTAL
Intervention: Distal aortic arch cannulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional cannulation of the ascending aorta (control group)
Number of subjects: 34
Study: 8684757

Group type: EXPERIMENTAL
Intervention: Immediate feeding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed feeding (control)
Number of subjects: 0
Study: 1649790

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 20 days (group A)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 30 days (group B)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 40 days (group C)
Number of subjects: 312
Study: 6401612

Group type: EXPERIMENTAL
Intervention: CO2-rebreathing indirect Fick method
Number of subjects: 15
Study: 29199652

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (6 fractions per week, 2 Gy per fraction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional fractionation (5 fractions per week, 2 Gy per fraction)
Number of subjects: 60
Study: 27654449

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 24718066

Group type: EXPERIMENTAL
Intervention: Kineflex-L Disc (investigational group)
Number of subjects: 457

Group type: COMPARATOR
Intervention: CHARITE artificial disc (control group)
Number of subjects: 457
Study: 22406657

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Carbamazepine with phenytoin
Number of subjects: 121
Study: 20663737

Group type: EXPERIMENTAL
Intervention: Low-NOx unflued gas heaters
Number of subjects: 400
Study: 17209164

Group type: EXPERIMENTAL
Intervention: Intradiscal and intraforaminal injections of a steroid, an anesthetic, and O(2)-O(3) mixture (group B)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Intradiscal and intraforaminal injections of a steroid and an anesthetic (group A)
Number of subjects: 159
Study: 15623834

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reduced iron + Na(2)EDTA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate and reduced iron + Na(2)EDTA
Number of subjects: 54
Study: 12218523

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.8‐2.5 vol%)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Isoflurane (0.5‐1.4 vol%)
Number of subjects: 116
Study: 10335537

Group type: EXPERIMENTAL
Intervention: Children with birthweight < 2500 g
Number of subjects: 861
Study: 7656629

Group type: EXPERIMENTAL
Intervention: Local radiotherapy (7 Gy, three daily sessions, 10 to 15 days after thoracoscopy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No radiotherapy (control group)
Number of subjects: 40
Study: 2789920

Group type: EXPERIMENTAL
Intervention: APD 30 mg single dose on day 1 (group A, n = 9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: APD 30 mg two consecutive doses on days 1 and 2 (group B, n = 9)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: APD 60 mg single dose on day 1 (group C, n = 9)
Number of subjects: 27
Study: 31785624

Group type: EXPERIMENTAL
Intervention: Short-term nutritional supplementation (greater energy content diet)
Number of subjects: 18
Study: 28634280

Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 134

Group type: COMPARATOR
Intervention: Endovascular coiling
Number of subjects: 134
Study: 27471018

Group type: EXPERIMENTAL
Intervention: S4HM intervention (interactive seminar, eHealth messaging, behavioral contract, parental newsletters)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: S4HM intervention
Number of subjects: 322
Study: 23793945

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide (10 mg/h)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Bolus of furosemide (20 mg/6 h)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Bolus of furosemide (20 mg/8 h)
Number of subjects: 109
Study: 23951788

Group type: EXPERIMENTAL
Intervention: Ozicure Oxygen Activator
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Opalescence Quick
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study: 21494186

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk administered 3 times daily for 8 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo administered 3 times daily for 8 weeks
Number of subjects: 74
Study: 17665424

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo/Infliximab
Number of subjects: 200
Study: 16186399

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day ramipril
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 5 mg/day ramipril
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12017397

Group type: EXPERIMENTAL
Intervention: Almotriptan 6.25 mg
Number of subjects: 1777

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 1777
Study: 9890408

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day for first 4 weeks, then 10 mg/day for second 4 weeks)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 250
Study: 7742162

Group type: EXPERIMENTAL
Intervention: Enoxacin with water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enoxacin with milk
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enoxacin with a standard breakfast
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enoxacin with a breakfast and milk
Number of subjects: 8
Study: 2048675

Group type: EXPERIMENTAL
Intervention: Neostigmine 15 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neostigmine 35 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neostigmine 55 micrograms/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neostigmine 75 micrograms/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Atracurium-induced neuromuscular block (control)
Number of subjects: 36
Study: 7338895

Group type: EXPERIMENTAL
Intervention: Cooling biofeedback training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Warming biofeedback training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Finger site biofeedback training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Temporal artery site biofeedback training
Number of subjects: 24
Study: 31185067

Group type: EXPERIMENTAL
Intervention: Network Scale Up (NSU) methodology using proportional method
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Network Scale Up (NSU) methodology using data-based method
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Direct estimate considered as gold standard
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Data-based method for calculating network size (C)
Number of subjects: 2500
Study: 27702624

Group type: EXPERIMENTAL
Intervention: 2.0 mg intravitreal aflibercept injections (IAIs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Macular laser
Number of subjects: 60
Study: 25956368

Group type: COMPARATOR
Intervention: ET ≥3
Number of subjects: 6073

Group type: COMPARATOR
Intervention: FHB >1
Number of subjects: 6073

Group type: COMPARATOR
Intervention: Nulliparity
Number of subjects: 6073
Study: 24052800

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occupational therapy (placebo)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual activities of the nursing home (control)
Number of subjects: 30
Study: 21407218

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus vinorelbine (GemVin)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus cisplatin (GemCis)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus capecitabine (GemCap)
Number of subjects: 141
Study: 19390280

Group type: EXPERIMENTAL
Intervention: Hernia sac laparoscopy (group A, 21 patients)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard management without laparoscopy (group B, 20 patients)
Number of subjects: 41
Study: 17380985

Group type: EXPERIMENTAL
Intervention: Experimental textbook
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control textbook (not explicitly named)
Number of subjects: 0
Study: 15039148

Group type: COMPARATOR
Intervention: Amino acid infusion (10% Travasol)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexamethasone (2 mg orally every 6 h for 3 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (10% Travasol) with dexamethasone
Number of subjects: 16
Study: 11511425

Group type: EXPERIMENTAL
Intervention: NPR‐C receptor density in patients with HF (class III‐IV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NPR‐C receptor density in patients with HF (class I‐II)
Number of subjects: 18

Group type: COMPARATOR
Intervention: NPR‐C receptor density in healthy controls
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of NPR‐C receptor density between class III‐IV HF patients and controls
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comparison of NPR‐C receptor density between class III‐IV HF patients and class I‐II HF patients
Number of subjects: 18
Study: 9477538

Group type: EXPERIMENTAL
Intervention: 5-session relationship violence prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7887101

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine‐1 (Meaverin)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1% procaine (Novocain)
Number of subjects: 600

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1% prilocaine (Xylonest)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (Xylocain)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: 1% mepivacaine‐2 (Scandicain)
Number of subjects: 600
Study: 3171102

Group type: EXPERIMENTAL
Intervention: Surgical peripheral iridectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Argon laser iridotomy
Number of subjects: 60